BridgeBio Pharma, Inc.

NasdaqGS:BBIO Stock Report

Market Cap: US$14.6b

BridgeBio Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:BBIO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 25SellUS$6,319,662Wen-Chaun LoIndividual95,599US$67.06
15 Oct 25SellUS$19,811,517Viking Global Investors LPCompany374,915US$57.13
21 Aug 25SellUS$2,090,081Thomas TrimarchiIndividual42,237US$49.48
07 Aug 25SellUS$45,440Maricel ApuliIndividual1,000US$45.44
04 Aug 25SellUS$39,464,941Viking Global Investors LPCompany832,105US$47.68
25 Jul 25BuyUS$424,772Viking Global Investors LPCompany9,368US$45.72
01 Jul 25BuyUS$2,711,754Viking Global Investors LPCompany64,189US$42.28
01 Jul 25SellUS$701,461Viking Global Investors LPCompany16,644US$42.15
27 Jun 25SellUS$154,000,000Viking Global Investors LPCompany3,500,000US$44.00
26 Jun 25SellUS$207,327Hannah ValantineIndividual4,707US$44.13
12 May 25SellUS$205,200,000KKR & Co. Inc.Company6,000,000US$34.20
02 May 25SellUS$3,849,900Wen-Chaun LoIndividual100,000US$38.50
02 May 25SellUS$39,509Maricel ApuliIndividual1,026US$38.51
05 Mar 25SellUS$197,760,000KKR & Co. Inc.Company6,000,000US$32.96
31 Jan 25SellUS$106,989,998Viking Global Investors LPCompany3,065,616US$34.90

Insider Trading Volume

Insider Buying: BBIO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of BBIO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders8,175,3034.14%
VC/PE Firms13,260,9716.72%
Hedge Funds15,893,9348.06%
Institutions159,937,16681.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 69.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.73%
The Vanguard Group, Inc.
16,832,059US$1.3b2.11%0.02%
8.25%
Viking Global Investors LP
15,893,934US$1.2b-0.53%3.05%
7.48%
BlackRock, Inc.
14,411,203US$1.1b1.06%0.01%
6.88%
KKR & Co. Inc.
13,260,971US$1.0b0%6.67%
4.54%
Janus Henderson Group plc
8,741,079US$660.9m-5.77%0.23%
4.25%
Farallon Capital Management, L.L.C.
8,192,000US$619.4m3.7%3.15%
3.16%
Aisling Capital Management LP
6,089,611US$460.4m0.35%79.67%
2.91%
State Street Global Advisors, Inc.
5,606,340US$423.9m-4.92%0.01%
2.88%
Neil Kumar
5,542,909US$419.1m-4.06%no data
2.03%
Geode Capital Management, LLC
3,909,941US$295.6m6.2%0.02%
2%
Frazier Life Sciences Management, LP
3,845,457US$290.8m1.18%7.35%
1.91%
Invesco Ltd.
3,684,408US$278.6m34.2%0.07%
1.61%
UBS Asset Management AG
3,099,685US$234.4m-11.9%0.02%
1.36%
T. Rowe Price Group, Inc.
2,619,244US$198.0m172%0.02%
1.21%
Two Sigma Investments, LP
2,328,941US$176.1m-0.43%0.28%
1.21%
AllianceBernstein L.P.
2,328,715US$176.1m-5.74%0.05%
1.17%
D. E. Shaw & Co., L.P.
2,252,762US$170.3m8.24%0.15%
1.02%
Norges Bank Investment Management
1,956,654US$147.9m0%0.01%
1%
Capital Research and Management Company
1,933,126US$146.2m-51.5%0.01%
1%
Nomura Investment Management Business Trust
1,933,096US$146.2m-7.74%0.19%
1%
Charles Schwab Investment Management, Inc.
1,925,198US$145.6m44.6%0.02%
0.99%
Manulife Asset Management
1,914,767US$144.8m1.23%0.1%
0.97%
Sequoia Capital Operations LLC
1,860,364US$140.7m0%0.71%
0.91%
Laurion Capital Management LP
1,753,544US$132.6m-27.3%17.08%
0.88%
FMR LLC
1,694,593US$128.1m-16.2%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/30 17:37
End of Day Share Price 2025/12/29 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BridgeBio Pharma, Inc. is covered by 32 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PickeringBernstein
Jason ZemanskyBofA Global Research
Joshua SchimmerCantor Fitzgerald & Co.